Evidence map›Paper›PMID 28483609›Full record

SynthesisChest2017

Reduced COPD Exacerbation Risk Correlates With Improved FEV

Alexander D Zider, Xiaoyan Wang, Russell G Buhr, Worawan Sirichana, Igor Z Barjaktarevic, Christopher B Cooper

Open access · greenAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Chest, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Longitudinal FEVInternational journal of chronic obstructive pulmonary disease
    Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Observational
  15. [Application of a multiple linear regression model of FEV1 in pulmonary function test].Nan fang yi ke da xue xue bao = Journal of Southern Medical University · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Alexander D ZiderDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Xiaoyan WangDivision of General Internal Medicine and Health Services Research, Department of Medicine, University of California, Los Angeles, Los Angeles, CA.
Russell G BuhrDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; Department of Health Policy & Management, Fielding School of Public Health, University of California, Los Angeles, Los Angeles, CA.
Worawan SirichanaDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Igor Z BarjaktarevicDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.
Christopher B CooperDivision of Pulmonary and Critical Care Medicine, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA; Department of Physiology, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA. Electronic address: ccooper@mednet.ucla.edu.
University of California, Los Angeles · USKing Chulalongkorn Memorial Hospital · TH

Funding

NRSA Training CoreTL1TR001883 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ALEX BUI, Nina Thawata Harawa · 2016 to 2026
$8.6M
NCATS NIH HHS TL1 TR001883NHLBI NIH HHS L30 HL134025
6 · The paper itself

Abstract

backgroundThe mechanism by which various classes of medication reduce COPD exacerbation risk remains unknown. We hypothesized a correlation between reduced exacerbation risk and improvement in airway patency as measured according to FEV

methodsBy systematic review, COPD trials were identified that reported therapeutic changes in predose FEV

resultsThe analysis of RD and RR included 119,227 patients, and the HR analysis included 73,475 patients. For every 100-mL change in predose FEV

conclusionsA significant correlation between increased FEV

Indexed as

Airway ResistanceDisease ProgressionForced Expiratory VolumeHumansPulmonary Disease, Chronic ObstructiveRegression AnalysisRiskCOPD exacerbationsCOPD mechanismsCOPD pharmacology

Identifiers

PMID28483609
PMCPMC6026240
OpenAlexW2610348280

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.